Get the latest tech news
'Breakthrough' dementia drug looks to stop disease in its tracks
Filamon Limited, an Australian biotech company focused on developing next-gen anti-inflammatory drugs, has announced its breakthrough dementia treatment. ALPHA-003 is designed to preserve the integrity of vital brain cell structures and protect them against destruction caused by brain inflammation.
Filamon Limited, an Australian biotech company focused on developing next-gen anti-inflammatory drugs, has announced its breakthrough dementia treatment. Now, an Australian biotech company, Filamon Limited, has announced its breakthrough treatment, ALPHA-003, which is aimed at halting the progression of dementia by preventing microtubular destruction. “ALPHA-003 was under development as a new form of anti-inflammatory drug that worked by blocking the activating effects of the key inflammatory ligand, hGIIA, on a range of cell structural proteins,” Professor Graham Kelly, Filamon’s co-founder, CEO, and Managing Director said in an interview with New Atlas.
Or read this on r/tech
